SNDK has never announced its earnings date this far in advance of the event to my knowledge as a 15+ year investor. History shows the earlier they announce that date, the better the earnings. Last quarter they didn't announce the earnings date in advance at all, which proved to be for a good reason as they issued the warning guidance instead. Wise investors will make good money here.
The news yesterday was not good but not insurmountable. The proof will be the oncology potential of Duvelisib and the partnership with AbbVie. If they hit their marks on those trials this stock will rocket given the low float. Management was wise to terminate the arthritis study when they did as it will cut expenses. Now it's time to develop drugs that will gain FDA approval. Let's see if they can execute.
The collaboration with AbbeVie is for oncology only and that's the most significant application, hence the $250M investment. INFI is hard to predict. A few years back, they announced similar bad news about drug trials only to rocket higher literally within weeks based on the Street's anticipation of successful results with another drug. Maybe this time will be the same, who knows?